Suspendu

DBMComparison of Allogenix Plus Demineralized Bone Matrix and Autogenous Bone Dust Versus Autogenous Bone Dust Alone in Ossification of Small Calvarial Defects, a Pilot Study.

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

Allogenix Plus

Biologique
Qui peut participer

De 18 à 36 mois
+2 critères d'éligibilité
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Étude thérapeutique

Phase 4
Interventionnel
Date de début : octobre 2009
Voir le détail du protocole

Résumé

Sponsor principalUniversity of Missouri-Columbia
Dernière mise à jour : 27 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 octobre 2009

Date à laquelle le premier participant a commencé l'étude.

The skull is made of multiple bones that are separated from each other at the time of birth through sutures (joints). These sutures (open spaces) allow for growth of the brain resulting in growth of the skull bones. These sutures close at different stages of life, the metopic suture is the earliest one to close at 2 years old and the latest at 26 years old. If these sutures (open spaces) close prematurely the patient develops craniosynostosis. This will result in lack of growth of the skull perpendicular to the suture line and increased growth parallel to the suture. There are different degrees of craniosynostosis that will result in anything from a slight ridge along the suture line to abnormal head shape causing constriction of the brain, developmental delays, and elevated intracranial pressure. Patients with significant abnormal head shape or patients showing any developmental delay will undergo surgical intervention. The surgery is called Cranial Vault Remodeling and it consists of opening the scalp to access the skull bones involved, then removing the bones from the underlying brain, reshaping and expanding the bone, and placing them back to protect the brain. The skull bones are held together with absorbable plates. Because the skull bones are expanded to allow for adequate brain growth there are gaps that are left without any bone. Some of these gaps are filled in with the left over small bony pieces. Other gaps are filled in with even smaller pieces of left over bone that is placed in a saw mill to form bone dust. Often, the amount of bone dust and bone pieces is not enough to fill in all the gaps. When the gaps are left unfilled it usually takes longer for these areas to be filled by the patient's own bone. This means that the brain underneath these gaps is left unprotected until they are covered with bone. At times, primarily in children 18 months or older, we find that these gaps are never fully filled requiring the child to undergo a second surgery in which bone is taken either from the ribs or the skull to fill in these gaps. Specific Aims: 1) Evaluate the efficacy of the bone substitute Allogenix Plus in ossification of small cranial defects in patients with metopic craniosynostosis forms exist. These are derived from cadaver graft material that have been determined eligible for transplantation by a qualified tissue bank medical director and communicable disease testing has been performed by a laboratory certified under CLIA. Allogenix Plus is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. The bone is further processed with hyaluronic acid to remove acid-soluble proteins in the bone, leaving behind other proteins, bone growth factors, and collagen. The demineralized bone matrix is then combined with lecithin a non-toxic lipid carrier derived from soybeans that is resistant to breakdown by body fluids. It also contains an additional synthetic material know as Pro Osteon Implant 500R. This naturally derived material is made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite. Following the conversion the material is no longer coral but a composite of highly resorbable calcium carbonate with a slower resorbing outer layer of calcium phosphate. The material retains the porous, interconnected architecture of coral which gives it a similar structure to cancellous bone, which provides a pathway for bony ingrowth. Allogenix Plus is osteoinductive, serves as a scaffold that will provide the framework necessary for bone growth, and osteoconductive, able to induce bone formation when placed into a site were bone may not normally grow. It has been approved for use in filling craniofacial defects and craniotomies that are no larger than 25 cm2. Material and Methods: In this study we will recruit 5 subjects of 18 months or older with metopic craniosynostosis who will receive Allogenix Plus and bone dust to fill in small calvarial gaps and compare them to a historical cohort that only received bone dust. The parents of new patients seen in clinic will be asked to participate on a voluntary basis until 5 subjects with of 18 months or older with metopic craniosynostosis undergoing fronto-orbital advancement and cranial vault remodeling have been recruited. They will be advised as to the risks and benefits of the study. Once informed consent has been obtained the patient's will undergo surgery. During surgery the calvarial defects less than 25 cm2 will be measured and filled in with a quantified amount of bone dust and a quantified amount of Allogenix Plus. Pictures will be taken of the different stages of the procedure as is currently standard of care. Once we are done with surgery the patient will obtain a Head CT scan in the immediate post-operative period, as is current standard of care. The patient will then receive our standard post-operative care. During clinic visits at 1 week, 3 weeks, 6 weeks, 12 weeks, 6 months, and 1 year we will evaluate for any potential complications including infection, rejection of transplanted material, and wound breakdown. One year after surgery the patient will undergo another CT of the Head. In this CT scan we will evaluate for bone formation, bone resorption, and bony gaps present. We will then obtain a historical cohort comprised of 5 patients that are age and sex matched to our 5 subjects who received Allogenix Plus by performing a chart review. We will compare through pictures, immediate post-operative CT scans of the Head, and 1 year post-operative CT scans of the Head the defect size and the and percent of ossification of defects with bone dust alone, which is our current standard of care, versus bone dust with Allogenix Plus.

Titre officielComparison of Allogenix Plus Demineralized Bone Matrix and Autogenous Bone Dust Versus Autogenous Bone Dust Alone in Ossification of Small Calvarial Defects, a Pilot Study.
NCT01006148
Sponsor principalUniversity of Missouri-Columbia
Dernière mise à jour : 27 janvier 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.

Traitement

Cette étude teste un ou plusieurs traitements pour évaluer leur efficacité contre une maladie ou un problème de santé spécifique. L'objectif est de voir si un nouveau médicament ou une thérapie fonctionne mieux, ou provoque moins d'effets secondaires que les options existantes.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

De 18 à 36 mois

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Critères

Un critère d'inclusion nécessaire pour participer
Children between the ages of 18 months and 36 months with metopic craniosynostosis undergoing cranial vault remodeling with defects 25 cm squared or less

Un critère d'exclusion empêche la participation
Allergic reaction to any of the components of the bone substitute Allogenic Plus.

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

Un seul groupe d'intervention est désigné dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

Expérimental
Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.

Objectifs de l'étude

Objectifs principaux

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Suspendu

University of Missouri Hospital and Clinics

Columbia, United StatesOuvrir University of Missouri Hospital and Clinics dans Google Maps
Suspendu1 Centres d'Étude